JANX - Massive Insider Trade At Janux Therapeutics | Benzinga
Jay Lichter, Director at Janux Therapeutics (NASDAQ:JANX), reported a large insider buy on November 15, according to a new SEC filing.
What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Lichter purchased 849,854 shares of Janux Therapeutics. The total transaction amounted to $4,988,642.
Janux Therapeutics shares are trading up 3.53% at $9.09 at the time of this writing on Thursday morning.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
The Importance of Insider Transactions
Insider transactions shouldn't be used primarily to make an investing decision, however an insider ...